BMJ report into top-selling diabetes drug raises concerns about the drug regulatory system
A BMJ investigation into the top-selling diabetes drug rosiglitazone (Avandia) raises concerns about its safety and the whole system by which drugs are evaluated, regulated, and promoted around the world.